MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$23,514K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of investments
Depreciation and amortization
Proceeds from ft819 cirm award
Others
Negative Cash Flow Breakdown
Purchases of investments
Net loss
Accretion and amortization of pr...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
-
-
6,646
-
Total operating expenses
-
-
154,350
-
Loss from operations
-
-
-147,704
-
Interest income
-
-
11,052
-
Change in fair value of stock price appreciation milestones
-
-
-127
-
Other income
-
-
93
-
Total other income
-
-
11,389
-
Net loss
-30,159
-31,213
-32,374
-32,250
Depreciation and amortization
2,780
2,918
3,063
3,227
Stock-based compensation
3,518
3,929
5,528
4,861
Accretion and amortization of premiums and discounts on investments, net
764
772
881
810
Deferred revenue
-582
200
377
4
Change in fair value of stock price appreciation milestones
580
80
-127
90
Impairment of long-lived assets
-
-
0
-
Loss on disposal of property and equipment
0
-
-45
0
Accounts receivable
-1
-212
233
-713
Prepaid expenses and other assets
-521
-132
-1,014
-1,026
Accounts payable and accrued expenses
1,256
-5,774
865
-550
Right-of-use assets and lease liabilities, net
-585
-534
-591
-685
Net cash used in operating activities
-23,434
-30,822
-23,314
-24,374
Proceeds from sale of property and equipment
0
-
237
3
Purchases of property and equipment
80
239
1,192
2,203
Purchases of investments
58,346
28,729
37,731
57,975
Maturities of investments
72,983
52,555
66,316
81,447
Net cash provided by investing activities
14,557
23,587
27,630
21,272
Issuance of common stock from equity incentive plans, net of issuance costs
412
-
0
0
Proceeds from public offering of common stock, net of issuance costs
-
-
0
0
Proceeds from issuance of pre-funded warrants, net of issuance costs
-
-
0
0
Proceeds from ft819 cirm award
1,324
-
1,490
0
Proceeds from ft836 cirm award
0
-
-200
-2,475
Net cash provided by financing activities
1,736
-
1,690
2,475
Net change in cash, cash equivalents and restricted cash
-7,141
-7,235
6,006
-627
Cash, cash equivalents and restricted cash at beginning of the period
49,620
56,855
50,849
46,283
Cash, cash equivalents and restricted cash at end of the period
42,479
49,620
56,855
50,849
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of investments
$72,983K
(-55.54%↓ Y/Y)
Proceeds from ft819 cirm
award
$1,324K
Issuance of common stock
from equity...
$412K
Net cash provided by
investing activities
$14,557K
(-76.62%↓ Y/Y)
Net cash provided by
financing activities
$1,736K
(31.02%↑ Y/Y)
Canceled cashflow
$58,426K
Net change in cash,
cash equivalents and...
-$7,141K
(-237.51%↓ Y/Y)
Canceled cashflow
$16,293K
Stock-based compensation
$3,518K
(-75.80%↓ Y/Y)
Depreciation and
amortization
$2,780K
(-57.95%↓ Y/Y)
Accounts payable and
accrued expenses
$1,256K
(113.44%↑ Y/Y)
Change in fair value of
stock price...
$580K
(380.19%↑ Y/Y)
Prepaid expenses and
other assets
-$521K
(83.40%↑ Y/Y)
Accounts receivable
-$1K
(99.95%↑ Y/Y)
Purchases of investments
$58,346K
(-41.32%↓ Y/Y)
Purchases of property and
equipment
$80K
(-96.87%↓ Y/Y)
Net cash used in
operating activities
-$23,434K
(59.87%↑ Y/Y)
Canceled cashflow
$8,656K
Net loss
-$30,159K
(57.93%↑ Y/Y)
Accretion and
amortization of premiums and...
$764K
(-60.10%↓ Y/Y)
Right-of-use assets and lease
liabilities, net
-$585K
(52.86%↑ Y/Y)
Deferred revenue
-$582K
(-48.09%↓ Y/Y)
Buy us a coffee
FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)